



**KAJARIA CERAMICS** 

**Building Materials** 

### Miss estimates on sharp margin contraction; maintain HOLD

- Weak Q2 on sharp margin contraction due to high share of outsourced sales volume and high overhead costs of new commissioned units
- Guidance for volume growth revised down to 9-10% (vs 11-12%) and margin to 15% (vs 15-17%) for FY25 based on the weak Q2 result
- Maintain HOLD with unchanged TP of Rs 1,450 as the future earnings potential is well captured in the current valuation

**Weak Q2:** KJC's Q2FY25 result came below our expectation (Revenue: -2%; EBITDA: -13%; APAT: -23%) mainly due to the sharp contraction in EBITDA margin (-255bps YoY to 13.5% vs +15.1% estimate). Overall, KJC revenue grew by 5.1% YoY, but EBITDA/APAT de-grew by 11.6%/21.9% in Q2FY25. However, KJC EBITDA grew at a nominal pace of 8.6% on a 5Y CAGR basis in Q2FY25.

**Key highlights:** KJC gained market share as its tiles volume (+8.4% YoY) grew at a better pace than the industry (~2-3%) in Q2FY25. However, tile segment EBIT was down 9.7% YoY in Q2FY25 due to margin contraction (-207bps YoY to 12.0%) on account of higher outsourced sales volume mix and high overhead of the newly-acquired Keronite unit. Non-tile segment revenue de-grew by 1.1% YoY in Q2FY25 as weak plywood sales (-25.6%) more than offset the impact of increased sales of bathware (+5.7%)/adhesives (+39.4%). Non-tile segment reported EBIT loss of Rs 107mn in Q2FY25 (vs profit of Rs 7.3mn in Q2FY24) largely attributable to losses incurred in the recently commissioned sanitaryware unit in Morbi.

**Guidance downgrade:** The company has lowered its tiles volume growth guidance to 9-10% (+11-12% earlier) and consolidated EBITDA margin guidance is expected to be around 15% (15-17% earlier) for FY25. The company aims to bring down the net working capital from 59 days in Mar'24 to 50 days by Mar'25. Tiles realisation is expected to remain stable over the next two quarters. The company plans to spend Rs 2.0bn in FY25 (H1FY25: Rs 1.35bn).

**Maintain HOLD with unchanged TP of Rs 1,450:** We maintain our HOLD rating on the stock as we believe strong earnings growth prospects (EPS to grow at 14% CAGR over FY24-FY27E) is quite well baked into the current valuations (the stock trades at 42.9x on 1Y forward P/E vs 5Y average of 41.7x). We have revised down our EPS estimates (-11.4%/-6.5%/-4.9% for FY25E/FY26E/FY27E) based on the weak Q2 result, but our TP remains at Rs 1,450 as we roll forward our valuation from Jun'26 to Sep'26. Our target P/E remains unchanged at 40x.

22 October 2024

Utkarsh Nopany research@bobcaps.in

#### Key changes

	Target	Rating	
	<►	<►	
Ticke	er/Price	KJC IN/Rs 1,287	
Mark	et cap	US\$ 2.4bn	
Free	float	53%	
3M A	DV	US\$ 3.4mn	
52wk	high/low	Rs 1,579/Rs 1,110	
Prom	noter/FPI/DII	47%/16%/28%	

Source: NSE | Price as of 22 Oct 2024

#### Key financials

Y/E 31 Mar	FY24A	FY25E	FY26E
Total revenue (Rs mn)	45,784	49,853	57,649
EBITDA (Rs mn)	6,997	7,138	8,622
Adj. net profit (Rs mn)	4,221	4,133	5,233
Adj. EPS (Rs)	26.5	25.9	32.9
Consensus EPS (Rs)	26.5	30.5	37.5
Adj. ROAE (%)	16.6	14.8	17.3
Adj. P/E (x)	48.6	49.6	39.2
EV/EBITDA (x)	29.6	29.0	24.1
Adj. EPS growth (%)	20.0	(2.1)	26.6
Source: Company, Bloomberg, BOB	CAPS Research		

### Stock performance



Source: NSE





## Fig 1 – Quarterly performance – Consolidated

(Rs mn)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	H1FY25	H1FY24	YoY (%)	BOBCAPS Q2FY25E	Variance (%)
Total operating income	11,793	11,216	5.1	11,137	5.9	22,930	21,859	4.9	12,079	(286)
Raw-Material expense	5,115	4,582	11.6	4,722	8.3	9,837	9,299	5.8		
Gross Profit	6,678	6,635	0.7	6,415	4.1	13,093	12,560	4.2		
Employee expense	1,443	1,300	11.1	1,394	3.6	2,837	2,436	16.5		
Energy costs	2,244	2,211	1.5	2,127	5.5	4,372	4,148	5.4		
Other expense	1,401	1,327	5.6	1,224	14.5	2,625	2,486	5.6		
EBITDA	1,589	1,797	(11.6)	1,671	(4.9)	3,260	3,489	(6.6)	1,827	(238)
D&A	406	361	12.5	421	(3.7)	827	666	24.2		
EBIT	1,183	1,436	(17.6)	1,249	(5.3)	2,432	2,823	(13.8)		
Interest cost	47	43	11.0	47	1.1	94	95	(1.3)		
Non-operating expense/(income)	(70)	(81)	(13.7)	(79)	(11.9)	(148)	(173)	(14.4)		
PBT	1,205	1,474	(18.2)	1,281	(5.9)	2,487	2,901	(14.3)		
Tax	350	366	(4.4)	358	(2.2)	708	702	0.9		
Reported PAT	855	1,108	(22.8)	923	(7.3)	1,779	2,199	(19.1)		
Minority Interest	13	29	(55.6)	25	(49.2)	38	45	(15.3)		
Reported PAT after Minority Interest	843	1,080	(21.9)	898	(6.2)	1,741	2,155	(19.2)	1,099	(256)
Adjusted PAT	843	1,080	(21.9)	898	(6.2)	1,741	2,155	(19.2)		
As % of net revenues			(bps)		(bps)			(bps)		
Gross margin	56.6	59.2	(252)	57.6	(97)	57.1	57.5	(36)		
Employee cost	12.2	11.6	65	12.5	(28)	12.4	11.1	123		
Power costs	19.0	19.7	(68)	19.1	(7)	19.1	19.0	9		
Other cost	11.9	11.8	5	11.0	90	11.4	11.4	7		
EBITDA margin	13.5	16.0	(255)	15.0	(153)	14.2	16.0	(175)		
Tax rate	29.0	24.8	420	27.9	109	28.5	24.2	428		
APAT margin	7.1	9.6	(248)	8.1	(92)	7.6	9.9	(227)		

Source: Company, BOBCAPS Research

## Fig 2 – Segment Performance

(Rs mn)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	H1FY25	H1FY24	YoY (%)
Revenue								
Tiles	10,717	10,129	5.8	10,048	6.7	20,764	19,791	4.9
- Own Manufacturing	5,873	5,705	3.0	5,585	5.2	1,146	1,110	3.2
- Subsidiaries	1,945	1,825	6.6	1,999	(2.7)	394	361	9.4
- Outsourcing	2,717	2,469	10.1	2,312	17.5	503	486	3.4
Non-Tile	1,076	1,088	(1.1)	1,089	(1.2)	2,165	2,068	4.7
- Bathware	901	853	5.7	910	(1.0)	181	169	7.2
- Plywood	175	235	(25.6)	179	(2.5)	35	38	(6.4)
- Adhesives	182	130	39.4	152	19.2	33	23	47.6
Total	11,793	11,216	5.1	11,137	5.9	22,930	21,859	4.9
EBIT margin (%)								
- Tile	12.0	14.1	(207)	12.6	(55)	12.3	13.9	(164)
- Non-Tile	(9.9)	0.7	(1060)	(1.5)	(848)	(5.7)	3.1	(879)
Total	10.0	12.8	(277)	11.2	(118)	10.6	12.9	(231)
Operational Data								
Tiles Sales Volume (msm)	28.7	26.5	8.4	27.0	6.4	55.7	51.5	8.2
Tiles Realisation (Rs/sqm)	367	378	(2.8)	367	0.1	367	380	(3.5)
Tiles EBIT per unit (Rs/sqm)	45	54	(16.7)	47	(4.1)	46	54	(14.4)
Source: Company BOBCARS Research								

Source: Company, BOBCAPS Research




## Earnings call highlights

- Tiles industry scenario: Tiles demand in the domestic market grew at a muted pace of 2-3% in Q2FY25 due to heavy rainfall in the months of Aug and Sep'24 and sustained weakness in the domestic market. Tiles exports de-grew by 15% YoY in in 5MFY25 due to the steep rise in ocean freight. The company expects demand conditions for the tile industry to improve in H2FY25 over H1FY25.
- Outlook: The company has lowered its tiles volume growth guidance to 9-10% (+11-12% earlier) and consolidated EBITDA margin guidance is expected to be around 15% (15-17% earlier) for FY25. The company aims to bring down the net working capital from 59 days in Mar'24 to 50 days by Mar'25. Tiles realisation is expected to remain stable over the next two quarters.
- Tiles market share: KJC has gained market share as its tile sales volume grew by 8.4% YoY (vs industry growth of 2-3%) in Q2FY25. Going ahead, the company aims to grow its tiles volume by 5-6% more than the industry. The company is selling at a lower price point (5-7%) in Kerala with two different names Primera and Technica under Kajaria's brand name to expand distribution network.
- Margin: Gross margin was down 98bps QoQ to 56.6% in Q2FY25 due to increase in share of outsourced volumes (+233bps QoQ to 26.6%). EBITDA margin contracted by 153bps QoQ to 13.5% in Q2FY25 due to lower gross margin, and higher overhead cost of newly-acquired Keronite tiles facility and newly commissioned sanitaryware facility.
- B2C:B2B mix: The company expects to increase the share of government project sales from 12% in FY24 to 12.5-13.0% in FY25 and 15% in FY26 as new project teams have been set up in the East, West and South regions.
- Nepal plant: KJC's greenfield 50:50 JV project in Nepal, of 5.1msm capacity was commissioned in Sep'24 at a cost of Rs 1.8bn. Nepal's tile industry's size is estimated to be Rs 25bn. The company expects the Nepal plant to be ramped up over the next 2-3 quarter period.
- Capex: The company plans to spend Rs 2.0bn in FY25 (H1FY25: Rs 1.35bn).
- Bathware: Revenue grew at a muted pace of 5.7% YoY in Q2FY25. Bathware margin came under pressure in Q2FY25 due to costs associated with the newly commenced sanitaryware plant in Morbi. Going ahead, the company expects bathware revenue to grow at 15% rate in FY25 and margin is also expected to improve from Q4FY25 with the ramp up of the new facility.
- Plywood: Revenue de-grew by 26% YoY in Q2FY25.
- Adhesive: Revenue grew by 26% YoY in Q2FY25. The company plans to set up an adhesives facility in Gailpur, Rajasthan, by Dec'24 at a cost of Rs 150mn.
- **Fuel:** Blended fuel price declined from Rs 38/SCM in Q2FY24 to Rs 37/SCM in Q2FY25 and it is expected to remain stable in the near future.




## Fig 3 – KJC's tile volumes grew at 8.4% YoY (5Y CAGR: +7.8%) in Q2FY25




Source: Company, BOBCAPS Research

## Fig 5 – Non-tile segment de-grew by 1.1% YoY (5Y CAGR: +16.8%) in Q2FY25 and...




Source: Company, BOBCAPS Research

# Fig 7 – KJC's revenue projected to grow at 13% CAGR over FY24-FY27E




Source: Company, BOBCAPS Research

## Fig 4 – Tile EBIT margin fell 207bps YoY to 12.0% in Q2FY25 on high overhead of newly acquired unit



## Fig 6 – ... EBIT margin was down sharply due to high overhead of newly-commissioned sanitaryware unit



Source: Company, BOBCAPS Research

# Fig 8 – KJC EBITDA margin is projected to be relatively stable at around 15.0% over medium term








Fig 9 – EPS forecast to grow at 14.0% CAGR over FY24-FY27E



# Fig 10 – KJC is likely to generate healthy return ratio over FY24-FY27E



Source: Company, BOBCAPS Research



## Valuation methodology


We maintain our HOLD rating on the stock as we believe the strong earnings growth prospect (EPS to grow at 14% CAGR over FY24-FY27E) is quite well baked into the current valuations (KJC trades at 42.9x on 1Y forward P/E vs 5Y average of 41.7x).


We have revised down our EPS estimates (-11.4%/-6.5%/-4.9% for FY25E/FY26E/FY27E) based on the weak Q2 result, but our TP remains at Rs 1,450 as we roll forward our valuation from Jun'26 to Sep'26. Our target P/E remains unchanged at 40x.

### Fig 11 – Revised Estimates

	New Old		New		Old		Change (%)		
Consolidated (Rs bn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Total operating income	49.9	57.6	66.4	50.9	58.9	67.9	(2.2)	(2.2)	(2.2)
EBITDA	7.1	8.6	10.0	7.8	9.2	10.6	(8.5)	(6.5)	(5.6)
EBITDA Margin	14.3	15.0	15.0	15.3	15.7	15.6	(99bps)	(69bps)	(55bps)
Adjusted PAT	4.1	5.2	6.3	4.7	5.6	6.6	(11.4)	(6.5)	(4.9)
EPS (Rs)	25.9	32.9	39.3	29.3	35.2	41.3	(11.4)	(6.5)	(4.9)

Source: BOBCAPS Research





Source: Bloomberg, BOBCAPS Research

### Fig 13 – Key assumptions

(%)	FY23A	FY24A	FY25E	FY26E	FY27E
Tile Volume Growth	11.0	6.3	9.0	12.0	12.0
Tile Realisation Growth	5.9	(3.3)	(1.2)	2.0	2.0
Tile Revenue Growth	17.5	2.8	7.7	14.3	14.2
Non-Tile Revenue Growth	26.0	20.2	18.5	25.4	21.3
Non-Tile Revenue Share	9.8	11.3	12.3	13.3	14.1

Source: Bloomberg, BOBCAPS Research



## **Key risks**

- Better-than-expected recovery in real estate demand and sharp improvement in non-tile segment margins are key upside risks to our estimates.
- Market share loss in tiles and a steep decline in tile exports from India are key downside risks.

## Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
Apollo Pipes	APOLP IN	0.2	512	650	HOLD
Astral	ASTRA IN	5.7	1,790	2,200	HOLD
Century Plyboards	CPBI IN	2.3	879	725	HOLD
Finolex Industries	FNXP IN	2.2	297	325	HOLD
Greenlam Industries	GRLM IN	0.8	500	560	HOLD
Greenpanel Industries	GREENP IN	0.6	378	365	HOLD
Greenply Industries	MTLM IN	0.5	364	400	HOLD
Hindware Home Innovation	HINDWARE IN	0.3	313	500	BUY
Kajaria Ceramics	KJC IN	2.4	1,287	1,450	HOLD
Prince Pipes & Fittings	PRINCPIP IN	0.7	524	750	BUY
Somany Ceramics	SOMC IN	0.3	682	900	BUY
Supreme Industries	SI IN	6.8	4,486	5,250	BUY

Source: BOBCAPS Research, NSE | Price as of 22 Oct 2024



## Financials

Income Statement					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Total revenue	43,819	45,784	49,853	57,649	66,405
EBITDA	5,934	6,997	7,138	8,622	9,968
Depreciation	1,329	1,480	1,665	1,774	1,885
EBIT	4,605	5,517	5,472	6,848	8,083
Net interest inc./(exp.)	(223)	(211)	(189)	(189)	(189)
Other inc./(exp.)	336	462	501	480	600
Exceptional items	14	0	0	0	0
EBT	4,705	5,768	5,784	7,139	8,493
Income taxes	1,163	1,435	1,525	1,797	2,138
Extraordinary items	79	0	0	0	0
Min. int./Inc. from assoc.	(18)	(113)	(126)	(109)	(94)
Reported net profit	3,445	4,221	4,133	5,233	6,261
Adjustments	69	0	0	0	0
Adjusted net profit	3,514	4,221	4,133	5,233	6,261

Balance She	et
-------------	----

Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
. ,					
Accounts payables	3,104	2,933	3,194	3,693	4,254
Other current liabilities	2,723	2,385	2,385	2,385	2,385
Provisions	82	278	302	350	403
Debt funds	2,093	1,706	1,700	1,773	1,868
Other liabilities	1,261	1,372	1,372	1,372	1,372
Equity capital	159	159	159	159	159
Reserves & surplus	23,109	26,006	28,268	31,131	34,557
Shareholders' fund	24,044	26,756	28,944	31,728	35,059
Total liab. and equities	33,305	35,429	37,896	41,300	45,340
Cash and cash eq.	3,938	5,141	4,441	3,957	3,800
Accounts receivables	6,012	6,194	6,745	7,800	8,984
Inventories	5,647	5,322	6,070	7,115	8,440
Other current assets	1,268	970	1,004	1,068	1,140
Investments	19	148	148	148	148
Net fixed assets	13,705	15,336	17,170	18,896	20,511
CWIP	817	679	679	679	679
Intangible assets	761	1,041	1,041	1,041	1,041
Deferred tax assets, net	207	185	185	185	185
Other assets	932	412	412	412	412
Total assets	33,305	35,429	37,896	41,300	45,340

#### Cash Flows

ousinnows					
Y/E 31 Mar (Rs mn)	FY23A	FY24A	FY25E	FY26E	FY27E
Cash flow from operations	2,995	6,568	4,751	5,417	6,100
Capital expenditures	(2,482)	(3,254)	(3,500)	(3,500)	(3,500)
Change in investments	(19)	(129)	0	0	0
Other investing cash flows	7	225	264	243	363
Cash flow from investing	(2,495)	(3,157)	(3,236)	(3,257)	(3,137)
Equities issued/Others	0	0	0	0	0
Debt raised/repaid	707	(387)	(6)	74	94
Interest expenses	(223)	(211)	(189)	(189)	(189)
Dividends paid	(1,433)	(1,912)	(1,872)	(2,370)	(2,836)
Other financing cash flows	143	302	(148)	(159)	(189)
Cash flow from financing	(806)	(2,208)	(2,214)	(2,644)	(3,119)
Chg in cash & cash eq.	(306)	1,203	(700)	(485)	(157)
Closing cash & cash eq.	3,938	5,141	4,441	3,957	3,800

Y/E 31 Mar (Rs)	FY23A	FY24A	FY25E	FY26E	FY27E
Reported EPS	21.6	26.5	25.9	32.9	39.3
Adjusted EPS	22.1	26.5	25.9	32.9	39.3
Dividend per share	9.0	12.0	11.8	14.9	17.8
Book value per share	146.2	164.3	178.4	196.4	217.9
Valuations Ratios					
Y/E 31 Mar (x)	FY23A	FY24A	FY25E	FY26E	FY27E
EV/Sales	4.7	4.5	4.2	3.6	3.1
EV/EBITDA	35.0	29.6	29.0	24.1	20.8
Adjusted P/E	58.3	48.6	49.6	39.2	32.7
P/BV	8.8	7.8	7.2	6.6	5.9
DuPont Analysis					
Y/E 31 Mar (%)	FY23A	FY24A	FY25E	FY26E	FY27E
Tax burden (Net profit/PBT)	74.7	73.2	71.5	73.3	73.7
Interest burden (PBT/EBIT)	102.2	104.6	105.7	104.2	105.1
EBIT margin (EBIT/Revenue)	10.5	12.1	11.0	11.9	12.2
Asset turnover (Rev./Avg TA)	131.6	129.2	131.6	139.6	146.5
Leverage (Avg TA/Avg Equity)	1.5	1.4	1.4	1.4	1.4
Adjusted ROAE	15.3	16.6	14.8	17.3	18.7
Ratio Analysis					
Y/E 31 Mar	FY23A	FY24A	FY25E	FY26E	FY27E
YoY growth (%)					
Revenue	18.3	4.5	8.9	15.6	15.2
EBITDA	(3.0)	17.9	2.0	20.8	15.6
Adjusted EPS	(7.0)	20.0	(2.1)	26.6	19.6
Profitability & Return ratios (%)					
EBITDA margin	13.5	15.3	14.3	15.0	15.0
EBIT margin	10.5	12.1	11.0	11.9	12.2
Adjusted profit margin	8.0	9.2	8.3	9.1	9.4
Adjusted ROAE	15.3	16.6	14.8	17.3	18.7
ROCE	18.9	21.0	19.5	21.9	23.5
Working capital days (days)					
Receivables	50	49	49	49	49
Inventory	47	42	44	45	46
Payables	26	23	23	23	23
Ratios (x)					
0	<b>.</b>		4.0		

2.0

2.6

26.1

1.9

2.6

29.0

(0.1)

1.9

2.6

36.2

(0.1)

2.0

2.6 42.7

(0.1)

2.1

2.3

20.6

Adjusted debt/equity
(0.1)
(0.1)

Source: Company, BOBCAPS Research | Note: TA = Total Assets
In the second se

Gross asset turnover

Net interest coverage ratio

Current ratio



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited** Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051** SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025** Brand Name: **BOBCAPS** Trade Name: www.barodaetrade.com



Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

#### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

 $BUY-\mbox{Expected return}>+15\%$ 

HOLD – Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### Ratings and Target Price (3-year history): KAJARIA CERAMICS (KJC IN)



B - Buy, H - Hold, S - Sell, A - Add, R - Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### **General disclaimers**

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

## **KAJARIA CERAMICS**



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or merchan banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

#### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.